| |
Tuesday, October 11, 2022 | 10am ET / 7am PT Join us to learn about common pitfalls for rAAV processing and ways to overcome the challenges. Key for a successful process are high viral genome productivity and full capsids in the harvest material, with high overall yield and efficient impurity removal. Register now.
|
|
Today's Big NewsOct 5, 2022 |
| By Nick Paul Taylor GSK’s anti-TIM-3 antibody is moving into a pivotal trial after hitting the mark in the midphase portion of the study, cementing the Big Pharma’s status as a front-runner in a thinning field featuring Novartis. |
|
|
|
By Max Bayer Eiger won't be nabbing emergency use authorization for its COVID treatment after all. The company says the FDA rejected the pathway citing concerns about the trial and the general state of the pandemic in the U.S. |
By James Waldron Following a shake-up at the top, OncoSec Medical is now reducing its workforce by almost half as it tightens its focus on its lead melanoma trial of its only clinical-stage candidate. |
By James Waldron Novo Nordisk added the final piece to the puzzle the Danish drugmaker wanted to complete before submitting its once-weekly insulin icodec to regulators next year. |
By Nick Paul Taylor Eliem Therapeutics’ would-be challenger to Biogen and Sage Therapeutics’ zuranolone is moving into a phase 2a clinical trial. The transatlantic biotech greenlit the study after a pharmacokinetic study cleared up drug exposure concerns raised in another clinical trial. |
By Gabrielle Masson The U.S. government has granted Vir Biotechnology a multi-year contract and the chance to make up to $1 billion in efforts to respond to public health emergencies and prepare for future pandemics prompted by the flu or other infectious diseases. |
By Fraiser Kansteiner After an indefinite commercial delay on its Shire-acquired rare disease drug this spring, Takeda’s yearslong Natpara manufacturing saga is drawing to a close. |
By Conor Hale The company’s Medical Imaging Suite will also serve as a gateway for the development of AI programs for quickly parsing patient scans. |
By Kevin Dunleavy Amid reports that AstraZeneca's Evusheld is ineffective against the latest subvariant of omicron, BA.4.6, the FDA has updated its fact sheet for the antibody combo. The agency now says the product can increase the risk of COVID-19 infection for variants that it does not neutralize. |
By Fraiser Kansteiner While much of the current migraine hubbub revolves around AbbVie's oral franchise and Pfizer's Nurtec ODT, a patent feud between a pair of veteran injectables has been quietly raging in the background. Early this week, Teva Pharmaceutical parried a riposte from Eli Lilly. |
Fierce podcastsDon't miss an episode |
| | This week on "Podnosis," we talk about how how frequent cyberattacks are impacting patient care and what hospitals and health systems can do to shore up their defenses. Also under discussion is how social drivers of health are finally being recognized by the CMS. |
|
|---|
|
|
| eBookIn this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
| eBookWith real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
| Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT Data |
| WhitepaperSaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
| WhitepaperRead about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
| WhitepaperThis paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
| eBook Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Ferma.AI, a Product of ZoomRx |
| eBookImprove patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
| Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
| VideoLearn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
| VideoCan an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
| Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
| eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
| Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
| Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
